Sign In
Buy CRSP
$56.95
+4.87 (+9.35%)
At Close: Jun 04, 2026
Wall Street Loves These 3 Growth Stocks -- Should You?
05:50am, Friday, 09'th Jun 2023
Brookfield Renewable has tremendous opportunities, thanks to carbon emission reduction efforts. CRISPR Therapeutics could soon have a blockbuster therapy on the market.
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
04:15pm, Tuesday, 06'th Jun 2023
An upcoming event has gene editing stocks rising today. Editas Medicine (NASDAQ: EDIT ) has announced plans to present some important trial data via a live webinar next week on June 12 at 8 a.m.
CRISPR Therapeutics: A Galaxy's Worth of Deep Value
07:45am, Wednesday, 31'st May 2023
Thanks to the game-changing nature of CRISPR/Cas9, the gene-editing revolution has begun in earnest. Still, Wall Street clearly has its doubts about one of the field's founding members.
3 Disruptors I Love Right Now
06:49am, Tuesday, 30'th May 2023
Alteryx is unlocking the power of data analytics for thousands of businesses. CRISPR Therapeutics is developing innovative treatments for serious diseases.
Prediction: These 2 Stocks Could Double In the Next Year
10:15am, Sunday, 28'th May 2023
CRISPR Therapeutics is awaiting approval for a potential multi-billion product. Axsome Therapeutics has several clinical and regulatory milestones ahead.
3 No-Brainer Stocks to Buy for Under $100 Right Now
06:14am, Saturday, 27'th May 2023
CRISPR Therapeutics could soon win approval for its first product. Novocure has big news on the way in a matter of days.
2 Supercharged Stocks to Buy With $100
05:30am, Saturday, 27'th May 2023
Demand is back for Carnival's cruises, and the company is progressing along the road to profitability. CRISPR Therapeutics may be months away from a regulatory decision -- and a potential product laun
2 Top Trends to Invest $5,000 in Right Now
09:40am, Thursday, 25'th May 2023
Vertex Pharmaceuticals is one of the few gene-editing companies that is already profitable. Brookfield Renewable Partners offers exposure to diverse parts of the renewable energy landscape.
Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health
05:30am, Thursday, 25'th May 2023
CRISPR Therapeutics may be close to launching its very first product. Teladoc Health has shifted its strategy to favor its goal of profitability.
Cathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying It
09:30am, Sunday, 21'st May 2023
Cathie Wood just sold quite a few shares of CRISPR Therapeutics, likely at a profit. The biotech could launch its first medicine in a year.
Crispr Therapeutics: Potential Beyond Current BLA Filing Of Exa-Cel
03:45pm, Thursday, 18'th May 2023
Patients are currently being enrolled by CRISPR Therapeutics AG in a potentially pivotal single-arm phase 2 study using CTX-110 for the treatment of patients with large B-cell lymphoma. CTX-110 was su
2 Stocks You'll Be Glad You Bought at These Prices
08:41am, Wednesday, 17'th May 2023
Airbnb's unique business model will continue to set it apart in the travel and tourism industry. CRISPR Therapeutics' near-term outlook is quite favorable.
2 Soaring Growth Stocks That Could Rocket Even Higher
05:41am, Tuesday, 16'th May 2023
Shares of CRISPR Therapeutics and Nanox have risen sharply in 2023. CRISPR Therapeutics is developing a slate of experimental gene therapies, and the first could earn approval this year.
CRISPR Therapeutics AG (CRSP) Presents at Bank of America Securities 2023 Health Care Conference (Transcript)
07:08pm, Saturday, 13'th May 2023
CRISPR Therapeutics AG (NASDAQ:CRSP ) Bank of America Securities 2023 Health Care Conference May 9, 2023 1:40 PM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Geoff Meacham -
Is CRISPR Therapeutics Stock a Buy Now?
08:45am, Saturday, 13'th May 2023
CRISPR is waiting to hear from the FDA regarding an approval for its lead therapy. The company is using gene editing to develop therapies in oncology and inherited blood disorders.
